Kamada (KMDA) Asset Writedowns and Impairment (2016 - 2025)

Kamada (KMDA) posted quarterly Asset Writedowns and Impairment of $1.3 million for Q2 2025, up 14.51% year-on-year from $1.2 million in Q2 2024, and up 14.51% on a QoQ basis from $1.2 million in Q2 2024.

Kamada (KMDA) Asset Writedowns and Impairment (2016 - 2025) Analysis & Trends

Kamada (KMDA) has reported Asset Writedowns and Impairment for 4 consecutive years, with $1.3 million the latest figure, recorded in Q2 2025.

  • Quarterly Asset Writedowns and Impairment rose 14.51% year-over-year to $1.3 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2.5 million (up 112.47% YoY) and the FY2024 annual result came in at $6.7 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment grew to $1.3 million in Q2 2025 per KMDA's latest filing, from $1.2 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for KMDA reached as high as $1.3 million in Q2 2025 and fell as low as $1.2 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.51 Bn 87.64 Bn -
2 Teva Pharmaceutical Industries 35.95 Bn 32.21 Bn 1.97 Bn
3 Zoetis 32.59 Bn 30.65 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.51 Bn 23.45 Bn 4.39 Bn
5 United Therapeutics 23.06 Bn 20.91 Bn 648.10 Mn
6 RedHill Biopharma 21.48 Bn 21.48 Bn -
7 Viatris 20.25 Bn 18.44 Bn 1.16 Bn
8 Neurocrine Biosciences 17.79 Bn 16.48 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Kamada 400.07 Mn 326.92 Mn 19.12 Mn

Historic Data

Download Data
DateValue
Jun 30, 2025 1.32 Mn
Jun 30, 2025 1.32 Mn
Jun 30, 2024 1.15 Mn
Jun 30, 2024 1.15 Mn
Dec 31, 2017 -3,000.00
Dec 31, 2017 -3,000.00
Dec 31, 2016 5,000.00
Dec 31, 2016 5,000.00
Mar 31, 2016 10,000.00
Mar 31, 2016 10,000.00